The efficacy outcomes in non-small cell lung cancer patients treated with PD axis inhibitor agents - a population-based study of the Vojvodina region

Background: By 2021, the FDA approved the use of the drugs pembrolizumab and atezolizumab in the first-line treatment of patients with high positivity of programmed death ligand-1 (PD-L1) in locally advanced and metastatic non-small-cell-lung cancer (NSCLC). This approval was the result of statistic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nensi Lalić (Author), Marko Bojović (Author), Daliborka Bursać (Author), Darijo Bokan (Author), Vesna Čeriman Krstić (Author), Ivan Kuhajda (Author), Biljana Parapid (Author), Sanja Tomić (Author), Aleksandar Šipka (Author)
Formato: Livro
Publicado em: Frontiers Media S.A., 2024-07-01T00:00:00Z.
Assuntos:
Acesso em linha:Connect to this object online.
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

Connect to this object online.

3rd Floor Main Library

Detalhes do Exemplar 3rd Floor Main Library
Área/Cota: A1234.567
Cód. Barras: 1 Disponível